Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Not Recruiting

Trial ID: NCT01083602


This study is designed to assess the effectiveness of the combination of Panobinostat plus Bortezomib and Dexamethasone in patients with relapsed and bortezomib refractory Multiple Myeloma.

Official Title

A Phase II, Multi-center, Single Arm, Open Label Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

Stanford Investigator(s)


Inclusion Criteria:

   1. Patient has a previous diagnosis of multiple myeloma, based on IMWG 2003 definitions.
   All three of the following criteria must have been met:

      - Monoclonal immunoglobulin (M component) on electrophoresis, and on immunofixation
      on serum or on total 24 hour urine

      - Bone marrow (clonal) plasma cells ≥ 10% or biopsy proven plasmacytoma

      - Related organ or tissue impairment (CRAB symptoms: anemia, hypercalcemia, lytic
      bone lesions, renal insufficiency, hyperviscosity, amyloidosis or recurrent

   2. Patient must have relapsed and refractory MM and must require treatment for the
   relapsed disease

   3. Patients must have received at least 2 prior lines of therapy which include an IMiD
   (thalidomide or lenalidomide)

   4. Patient must be refractory to the last bortezomib containing line of therapy given in
   the relapsed and refractory setting defined as:

      - having progressed on or within 60 days of the last bortezomib-containing line of

   5. Patient has measurable disease on M protein at study screening defined by at least one
   of the following measurements as per thresholds clarified in IMWG 2003 disease
   definitions (Kyle, et al 2003):

      - Serum M-protein ≥ 1 g/dL (≥ 10 g/L)

      - Urine M-protein ≥ 200 mg/24 h

   6. Patients treated with local radiotherapy with or without concomitant exposure to
   steroids for pain control or management of cord/nerve root compression, are eligible.
   Two weeks must have lapsed since last date of radiotherapy, which is recommended to be
   a limited field. Patients who require concurrent radiotherapy should have entry to the
   protocol deferred until the radiotherapy is completed and 2 weeks have passed since
   the last date of therapy

   7. Patient's age is ≥ 18 years at time of signing the informed consent

   8. Patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of ≤

   9. Patient has the following laboratory values within 3 weeks before starting study drug
   (lab tests may be repeated, as clinically indicated, to obtain acceptable values
   before screen fail is concluded but supportive therapies are not to be administered
   within the week prior to screening tests for absolute neutrophil count or platelet

      - Absolute neutrophil count (ANC) ≥ 1.0 x 109 /L

      - Platelet count ≥ 70 x 109 /L

      - Serum potassium, magnesium, phosphorus, within normal limits (WNL) for

      - Total calcium (corrected for serum albumin) or ionized calcium ≥ LLN, and not
      higher than CTCAE grade 1 in case of elevated value

   Note: Potassium, calcium, magnesium, and/or phosphorus supplements may be given to
   correct values that are < LLN:

      - AST/SGOT and ALT/SGPT ≤ 2.5 x ULN

      - Serum total bilirubin ≤ 1.5 ULN (or ≤ 3.0 x ULN if patient has Gilbert syndrome)

      - Serum creatinine levels ≤ 2.5 x ULN, or calculated creatinine clearance ≥ 40

10. Patient has provided written informed consent prior to any screening procedures

11. Patient is able to swallow capsules

12. Patient must be able to adhere to the study visit schedule and other protocol

13. Women of childbearing potential (WOCBP) must have a negative serum pregnancy test at
   within 7 days prior to start of study treatment

Exclusion Criteria:

   1. Primary refractory disease (patients that never reached at least an MR for over 60
   days under any prior therapy)

   2. Patients who have a history of prior MM treatment with a DAC inhibitor including

   3. Patients who have had prior allogeneic stem cell transplantation and show evidence of
   active graft-versus-host disease that requires immunosuppressive therapy

   4. Peripheral neuropathy ≥ CTCAE grade 2

   5. Patients who will need valproic acid for any medical condition during the study or
   within 5 days prior to the first administration of study drug / treatment or who
   cannot be switch to safely to alternative anti-epileptic medication

   6. Patients who have impaired cardiac function including any of the following:

      - Congenital long QT syndrome, complete left bundle branch block or use of a
      permanent cardiac pacemaker, history or presence of ventricular tachyarrhythmias,
      clinically significant resting bradycardia (< 50 beats per minute). Right bundle
      branch block + left anterior hemiblock (bifascicular block)

      - QTcF > 450 msec on screening ECG

      - Presence of unstable atrial fibrillation. Patients with stable atrial
      fibrillation are allowed in the study provided they do not meet other cardiac or
      prohibited drug exclusion criteria

      - Previous history of angina pectoris or acute MI within 6 months

      - Congestive heart failure (New York Heart Association functional classification

      - Patient has any other clinically significant cardiovascular disease (e.g.
      uncontrolled hypertension)

   7. Patient has an impairment of gastrointestinal (GI) function or GI disease that may
   significantly alter the absorption of panobinostat (e.g., ulcerative disease,
   uncontrolled nausea, vomiting, malabsorption syndrome, obstruction, or significant
   small bowel resection)

   8. Patient has unresolved diarrhea ≥ CTCAE grade 2

   9. Patients who have any other concurrent severe and/or uncontrolled medical condition(s)
   including, but not limited to: uncontrolled diabetes mellitus, active or uncontrolled
   infection, chronic obstructive or chronic restrictive pulmonary disease (e.g. dyspnea
   at rest from any cause), symptomatic thyroid dysfunction, significant bleeding
   tendency, that could cause unacceptable safety risks or compromise compliance with the

10. Patients who are using medications that have a known relative risk of prolonging the
   QT interval or of inducing Torsade de Pointes, where such treatment cannot be
   discontinued or switched to a different medication prior to starting study drug

11. Women who are pregnant or breast feeding

12. Patients with evidence of another malignancy not in remission or history of such a
   malignancy within the last 5 years (except for treated basal or squamous cell
   carcinoma, or in situ cancer of the cervix)

13. Patients who have received prior to starting study treatment either radiation therapy
   to > 30% of marrow-bearing bone within 4 weeks; myelotoxic chemotherapy within 4
   weeks; or immunotherapy within 8 weeks; or who have not yet recovered from side
   effects of such therapies

14. Patients with any significant history of non-compliance to medical regimens or
   unwilling or unable to comply with the instructions given to him/her by the study

15. Use of chemo-, biologic or immunologic therapy and/or other investigational agents
   while the patient is on study treatment.

16. Patient taking any anti-cancer therapy concomitantly (bisphosphonates are permitted
   only if commenced prior to the start of screening period)


drug: panobinostat

drug: bortezomib

drug: dexamethasone

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Cancer Clinical Trials Office

New Trial Alerts